OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Understanding and targeting resistance mechanisms in cancer
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 107
Zi‐Ning Lei, Tian Qin, Qiu‐Xu Teng, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 107
Showing 1-25 of 107 citing articles:
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 32
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2478-2478
Open Access | Times Cited: 32
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Yuxuan Peng, Shuang Liang, Qian‐Fang Meng, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 21
Yuxuan Peng, Shuang Liang, Qian‐Fang Meng, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 21
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
Kenneth K.W. To, Zoufang Huang, Hang Zhang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101058-101058
Closed Access | Times Cited: 20
Kenneth K.W. To, Zoufang Huang, Hang Zhang, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101058-101058
Closed Access | Times Cited: 20
A comprehensive review of computational cell cycle models in guiding cancer treatment strategies
Chenhui Ma, Evren Gürkan-Çavusoglu
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Chenhui Ma, Evren Gürkan-Çavusoglu
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review
Alireza Shoari
Targets (2024) Vol. 2, Iss. 2, pp. 104-125
Open Access | Times Cited: 8
Alireza Shoari
Targets (2024) Vol. 2, Iss. 2, pp. 104-125
Open Access | Times Cited: 8
Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems
Matteo Perra, Ines Castangia, Matteo Aroffu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Matteo Perra, Ines Castangia, Matteo Aroffu, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering
Rama Edaibis, Raneem Akel, Jumi A. Shin
Transcription (2025), pp. 1-19
Closed Access | Times Cited: 1
Rama Edaibis, Raneem Akel, Jumi A. Shin
Transcription (2025), pp. 1-19
Closed Access | Times Cited: 1
Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review
Zahra Zahedifard, Shirin Mahmoodi, Abdolmajid Ghasemian
Biotechnology and Applied Biochemistry (2025)
Closed Access | Times Cited: 1
Zahra Zahedifard, Shirin Mahmoodi, Abdolmajid Ghasemian
Biotechnology and Applied Biochemistry (2025)
Closed Access | Times Cited: 1
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 1
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 1
Emerging biomarkers and molecular targets for precision medicine in cervical cancer
Pankaj Garg, Madhu Krishna, Ayalur Raghu Subbalakshmi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189106-189106
Closed Access | Times Cited: 7
Pankaj Garg, Madhu Krishna, Ayalur Raghu Subbalakshmi, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189106-189106
Closed Access | Times Cited: 7
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Hyeonji Yoo, Yeonjin Kim, Jinseong Kim, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 3994-3994
Open Access | Times Cited: 7
Hyeonji Yoo, Yeonjin Kim, Jinseong Kim, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 3994-3994
Open Access | Times Cited: 7
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 29-38
Closed Access | Times Cited: 7
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 29-38
Closed Access | Times Cited: 7
A state-of-art of underlying molecular mechanisms and pharmacological interventions/nanotherapeutics for cisplatin resistance in gastric cancer
Jitendra Gupta, Abdulrahman T. Ahmed, Nahla A. Tayyib, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115337-115337
Open Access | Times Cited: 15
Jitendra Gupta, Abdulrahman T. Ahmed, Nahla A. Tayyib, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115337-115337
Open Access | Times Cited: 15
Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 13
Liqin Yao, Qingqing Wang, Wenxue Ma
Cancers (2023) Vol. 15, Iss. 24, pp. 5857-5857
Open Access | Times Cited: 13
Molecular Modeling Studies to Probe the Binding Hypothesis of Novel Lead Compounds against Multidrug Resistance Protein ABCB1
Yasmeen Cheema, Kenneth J. Linton, Ishrat Jabeen
Biomolecules (2024) Vol. 14, Iss. 1, pp. 114-114
Open Access | Times Cited: 5
Yasmeen Cheema, Kenneth J. Linton, Ishrat Jabeen
Biomolecules (2024) Vol. 14, Iss. 1, pp. 114-114
Open Access | Times Cited: 5
CAR-T cell-derived exosomes: a new perspective for cancer therapy
Farnaz Sani, Shabnam Shojaei, Seyed Amirhossein Tabatabaei, et al.
Stem Cell Research & Therapy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Farnaz Sani, Shabnam Shojaei, Seyed Amirhossein Tabatabaei, et al.
Stem Cell Research & Therapy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Lorena Ostios-García, Daniel Martínez-Pérez, Beatriz Castelo, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1561-1571
Open Access | Times Cited: 5
Lorena Ostios-García, Daniel Martínez-Pérez, Beatriz Castelo, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1561-1571
Open Access | Times Cited: 5
Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy
Bemrew Admassu Mengistu, Tirunesh Tsegaw, Yitayew Demessie, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Bemrew Admassu Mengistu, Tirunesh Tsegaw, Yitayew Demessie, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer
Amy Rees, Evan D. Villamor, Della Evans, et al.
Genes (2025) Vol. 16, Iss. 1, pp. 42-42
Open Access
Amy Rees, Evan D. Villamor, Della Evans, et al.
Genes (2025) Vol. 16, Iss. 1, pp. 42-42
Open Access
Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies
Yunhan Tan, Siyuan Qin, Zhe Zhang, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access
Yunhan Tan, Siyuan Qin, Zhe Zhang, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access
Identification of Natural Phytochemicals as AKT2 Inhibitors Using Molecular Docking and Dynamics Simulations as Potential Cancer Therapeutics
Jibon Kumar Paul, Mahir Azmal, Md. Naimul Haque Shohan, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41897-e41897
Open Access
Jibon Kumar Paul, Mahir Azmal, Md. Naimul Haque Shohan, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41897-e41897
Open Access
Inhibition of Glutamine Metabolism Suppresses Tumor Progression through Remodeling of the Macrophage Immune Microenvironment
Tianhe Li, Sepehr Akhtarkhavari, Tiffany Chang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Tianhe Li, Sepehr Akhtarkhavari, Tiffany Chang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, et al.
Journal of Neuro-Oncology (2025)
Open Access
Rebeca Yakubov, Ramneet Kaloti, Phooja Persaud, et al.
Journal of Neuro-Oncology (2025)
Open Access
